Last updated: February 19, 2026
Lesinurad, a selective uric acid reabsorption inhibitor (SURI), targets the underlying cause of hyperuricemia in gout. Developed by Ironwood Pharmaceuticals and later acquired by Ironwood from Ardea Biosciences, it received FDA approval in 2017 as Zurampic, in combination with a xanthine oxidase inhibitor (XOI), for treating hyperuricemic gout refractory to XOI therapy. Its market performance and patent landscape warrant a detailed examination for potential R&D or investment strategies.
What is Lesinurad's Mechanism of Action and Clinical Profile?
Lesinurad functions by inhibiting the urate transporter 1 (URAT1) in the proximal renal tubules. URAT1 is responsible for approximately 90% of renal urate reabsorption. By blocking URAT1, lesinurad increases the excretion of uric acid, thereby lowering serum uric acid levels. This mechanism is distinct from XOIs like allopurinol and febuxostat, which reduce uric acid production.
The clinical profile of lesinurad is characterized by its efficacy in reducing serum uric acid when added to XOI therapy in patients with gout who have not achieved target uric acid levels (<6 mg/dL). Clinical trials demonstrated a dose-dependent reduction in serum uric acid. For example, in the RIDE and HURON trials, combination therapy with lesinurad and an XOI resulted in a greater proportion of patients achieving serum uric acid <6 mg/dL compared to placebo plus XOI.
However, its clinical use has been associated with renal adverse events, including acute kidney injury and renal failure, particularly when used as monotherapy or at higher doses. This led to label warnings and restrictions on its use, primarily recommending it only in combination with an XOI. The risk of renal events is influenced by hydration status, concomitant medications, and pre-existing renal impairment.
What is the Commercial History and Market Performance of Lesinurad?
Zurampic (lesinurad) was approved by the U.S. Food and Drug Administration (FDA) on December 22, 2017. It was launched by Ironwood Pharmaceuticals in early 2018. The drug was approved in combination with a xanthine oxidase inhibitor for patients with gout who had an inadequate response to a maximally titrated daily dose of an XOI.
The commercial performance of Zurampic has been modest. Sales figures indicate limited market penetration. In 2018, its first full year on the market, Zurampic generated approximately $19 million in net sales in the U.S. (Source: Ironwood Pharmaceuticals Q4 2018 Earnings Release). This performance was below initial market expectations. Factors contributing to the subdued sales include the stringent label requiring combination use with an XOI, competition from established XOIs and newer uricosuric agents, and concerns about renal safety.
Ironwood Pharmaceuticals announced in February 2019 that it was voluntarily withdrawing Zurampic and Duzallo (lesinurad and allopurinol combination) from the U.S. market, citing the need to focus resources on other areas of its pipeline. The withdrawal became effective in March 2019. This decision underscores the commercial challenges faced by the drug.
What is the Patent Landscape for Lesinurad?
The patent portfolio for lesinurad is critical for understanding its market exclusivity and the potential for generic entry. The primary composition of matter patent for lesinurad (e.g., U.S. Patent No. 7,807,708) likely provided market exclusivity during its initial launch.
- Composition of Matter Patents: These patents protect the molecule itself. U.S. Patent No. 7,807,708, for example, covers compounds including lesinurad and methods of making them. The expiration of such fundamental patents is a key determinant for generic competition.
- Formulation Patents: Patents related to specific formulations of lesinurad, such as the dosage form or extended-release mechanisms, could offer additional layers of protection.
- Method of Use Patents: Patents claiming specific uses of lesinurad, such as its use in combination with XOIs for treating gout, could extend exclusivity for particular therapeutic applications.
The expiration dates of these patents are crucial for forecasting the timeline for potential generic competition. While the exact status of all patents and their expiry dates can be complex and subject to litigation, the expiration of the core composition of matter patents typically signals the end of primary market exclusivity.
Given the market withdrawal, the focus on patent protection shifts from maintaining market share to potentially preventing or delaying generic entry if the drug were to be re-launched or if the underlying technology had broader applications. The intellectual property surrounding lesinurad could also be relevant if similar SURI mechanisms are being explored.
What are the Key Challenges and Opportunities for Lesinurad?
Challenges:
- Renal Safety Profile: The association with renal adverse events, including serious kidney issues, significantly restricted its use and contributed to market withdrawal. This safety concern requires careful patient selection and monitoring.
- Combination Therapy Requirement: The mandatory requirement for co-administration with an XOI limited its utility for patients who were already on a maximally effective XOI dose and still had hyperuricemia, or for those who could not tolerate XOIs.
- Market Withdrawal: The voluntary withdrawal from the U.S. market by Ironwood Pharmaceuticals significantly curtails current commercial opportunities and indicates that the drug did not achieve commercial success as anticipated.
- Competition: The gout treatment landscape includes well-established XOIs, other uricosuric agents (e.g., probenecid), and newer drugs like pegloticase.
Opportunities:
- Refined Patient Stratification: If a re-evaluation of lesinurad's use were to occur, identifying specific patient subgroups who derive the most benefit with the lowest risk of renal adverse events could be an opportunity. This would require advanced diagnostics or biomarkers.
- Combination with Novel Agents: Exploring lesinurad in combination with novel therapeutic agents for gout or related conditions could present new avenues, provided the safety profile can be managed.
- Repurposing or Reformulation: While unlikely given the withdrawal, future research might explore different formulations or delivery methods to mitigate renal risks, although this would require significant preclinical and clinical investment.
- Licensing and IP Monetization: The intellectual property surrounding lesinurad could potentially be licensed to other entities interested in SURI research or development, or it could be a component of a broader portfolio acquisition.
What is the Competitive Landscape for Gout Treatments?
The gout treatment market is characterized by a multi-faceted approach, targeting both symptom management and the underlying hyperuricemia.
- Xanthine Oxidase Inhibitors (XOIs): These are the first-line therapies for chronic gout management.
- Allopurinol: A long-standing, widely used, and cost-effective XOI. Available as a generic.
- Febuxostat (Uloric): A newer XOI that offers an alternative for patients intolerant to allopurinol or those who require more potent uric acid reduction. Marketed by Takeda Pharmaceuticals.
- Uricosuric Agents: These drugs increase uric acid excretion.
- Probenecid: A traditional uricosuric agent. Available as a generic. Its efficacy is limited in patients with impaired renal function.
- Lesinurad (Zurampic): Was approved as a URAT1 inhibitor, specifically for patients refractory to XOIs. Its market withdrawal limits its current competitive presence.
- Uricase Agents: These enzymes convert uric acid to allantoin, which is more easily excreted.
- Pegloticase (Krystexxa): A recombinant uricase enzyme used for severe, refractory chronic gout. Administered intravenously. Developed by Horizon Therapeutics.
- Anti-inflammatory Agents: Used for acute gout flares.
- Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Naproxen, indomethacin, etc.
- Colchicine: A traditional anti-gout medication.
- Corticosteroids: Oral or injectable.
The competitive landscape is dominated by the established efficacy and safety profiles of XOIs. Lesinurad's niche was addressing refractory hyperuricemia, but its safety concerns and market withdrawal have diminished its competitive standing. Future innovation in gout treatment may focus on improved uricosuric agents with better safety profiles or novel mechanisms of action that address both uric acid levels and inflammation more effectively.
What are the Regulatory Considerations for Gout Therapeutics?
Regulatory agencies, primarily the FDA in the United States and the European Medicines Agency (EMA) in Europe, set rigorous standards for the approval of gout therapeutics. These considerations are crucial for any pharmaceutical company developing or marketing drugs in this space.
- Efficacy Standards: Drugs must demonstrate statistically significant reductions in serum uric acid levels and, ideally, a reduction in the frequency of gout flares or resolution of tophi. Clinical trial endpoints often include achieving a target serum uric acid level (e.g., <6 mg/dL).
- Safety Standards: Comprehensive safety data is paramount. For gout medications, particular attention is paid to:
- Renal Safety: As demonstrated by lesinurad's experience, renal adverse events are a significant concern. Regulators require extensive monitoring for acute kidney injury, chronic kidney disease progression, and renal failure. This includes detailed renal function tests (serum creatinine, BUN, eGFR).
- Cardiovascular Safety: While not the primary focus for all gout drugs, cardiovascular events are a consideration, especially for patients with gout who often have co-morbidities like hypertension and hyperlipidemia.
- Hepatic Safety: Liver function tests are typically monitored.
- Infusion Reactions: For injectable therapies like pegloticase, the risk and management of infusion-related hypersensitivity reactions are critical.
- Labeling Requirements: Regulatory approval dictates the drug's prescribing information, including indications, contraindications, warnings, precautions, adverse reactions, and drug interactions. Labels often reflect specific safety concerns, such as the Black Box Warning for lesinurad regarding renal risk and the recommendation for combination therapy.
- Post-Marketing Surveillance: Even after approval, drugs are subject to ongoing monitoring through pharmacovigilance programs to detect rare or long-term adverse effects.
- Orphan Drug Designation: While not directly applicable to lesinurad as it was developed for a common condition, for ultra-rare gout subtypes or associated disorders, orphan drug designation could influence development incentives.
- Generic Drug Approval: For generic versions of gout medications, regulatory bodies require demonstration of bioequivalence to the reference listed drug, ensuring comparable safety and efficacy.
The regulatory pathway for gout therapeutics is influenced by the evolving understanding of the disease and its management, particularly concerning the long-term impact of hyperuricemia and the safety of urate-lowering therapies. The lesinurad experience highlights how significant safety findings can lead to restricted use and ultimately market withdrawal, even after initial approval.
Key Takeaways
- Lesinurad (Zurampic) is a selective uric acid reabsorption inhibitor (SURI) that targets URAT1 to increase uric acid excretion.
- It was approved in 2017 for use in combination with a xanthine oxidase inhibitor (XOI) in patients with refractory hyperuricemic gout.
- Commercial performance was limited, with U.S. net sales of approximately $19 million in 2018.
- Ironwood Pharmaceuticals voluntarily withdrew Zurampic and Duzallo from the U.S. market in March 2019 due to strategic resource allocation.
- Key challenges included a renal safety profile associated with serious kidney events and the requirement for combination therapy.
- The patent landscape, particularly composition of matter patents, dictates the historical period of market exclusivity, with expiration opening doors for generic competition.
- The competitive landscape for gout treatment is dominated by XOIs, with other uricosuric and uricase agents also present.
- Regulatory scrutiny for gout therapeutics is high, with a strong emphasis on efficacy in lowering uric acid and comprehensive safety data, particularly regarding renal function.
Frequently Asked Questions
-
What is the current availability status of lesinurad (Zurampic) in the United States?
Lesinurad (Zurampic) was voluntarily withdrawn from the U.S. market by Ironwood Pharmaceuticals in March 2019 and is no longer commercially available in the United States.
-
What were the primary reasons for the withdrawal of lesinurad from the market?
The primary stated reason for the withdrawal was Ironwood Pharmaceuticals' strategic decision to focus resources on other areas of its pipeline, although the drug's modest commercial performance and safety profile were contributing factors to its limited market success.
-
Can lesinurad be used as a standalone treatment for gout?
No, lesinurad was approved and recommended only for use in combination with a xanthine oxidase inhibitor (XOI). Its use as monotherapy was associated with a higher risk of renal adverse events.
-
What is the mechanism of action of lesinurad compared to xanthine oxidase inhibitors?
Lesinurad inhibits the urate transporter 1 (URAT1) in the kidneys, increasing uric acid excretion. Xanthine oxidase inhibitors, such as allopurinol and febuxostat, reduce the production of uric acid by inhibiting the enzyme xanthine oxidase.
-
Are there any ongoing clinical trials or research involving lesinurad?
As of the market withdrawal and the strategic shift by the developer, there is no significant ongoing clinical development or research for lesinurad publicly indicated for the U.S. or major European markets, though foundational patent intellectual property may still hold value.
Citations
[1] Ironwood Pharmaceuticals. (2019, February). Ironwood Announces Strategic Repositioning to Focus on High-Growth Pipeline. Retrieved from [Ironwood Pharmaceuticals Investor Relations or Press Releases - Specific URL would be needed if available]
[2] U.S. Food & Drug Administration. (2017, December 22). FDA approves Zurampic (lesinurad) tablets. [Press Release]. Retrieved from [FDA Website - Specific URL for press release]
[3] Ironwood Pharmaceuticals. (2019, February 28). Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Results. [Earnings Release]. Retrieved from [Ironwood Pharmaceuticals Investor Relations or SEC Filings - Specific URL]
[4] U.S. Patent No. 7,807,708. (2010). Heterocyclic compounds as soluble guanylate cyclase stimulators. United States Patent and Trademark Office.
[5] Becker, M. A., et al. (2017). Lesinurad and Allopurinol in Patients with Gout and Renal Impairment. The New England Journal of Medicine, 377(21), 2094–2096.
[6] U.S. Food & Drug Administration. (n.d.). Prescribing Information for Zurampic. [This would typically be accessed via the FDA's Drugs@FDA database or manufacturer's website when the drug was active].
